HUP0401097A2 - Karbociklusos hidrazinovegyületek, mint a réztartalmú aminoxidázok inhibitorai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények - Google Patents

Karbociklusos hidrazinovegyületek, mint a réztartalmú aminoxidázok inhibitorai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0401097A2
HUP0401097A2 HU0401097A HUP0401097A HUP0401097A2 HU P0401097 A2 HUP0401097 A2 HU P0401097A2 HU 0401097 A HU0401097 A HU 0401097A HU P0401097 A HUP0401097 A HU P0401097A HU P0401097 A2 HUP0401097 A2 HU P0401097A2
Authority
HU
Hungary
Prior art keywords
optionally substituted
alkyl
hydrogen atom
diseases
different
Prior art date
Application number
HU0401097A
Other languages
English (en)
Inventor
David John Smith
Ferenc Fülöp
Marjo Pihlavisto
László Lázár
Sakari Alaranta
Petri Vainio
Zsolt Szakonyi
Original Assignee
Biotie Therapies Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotie Therapies Corporation filed Critical Biotie Therapies Corporation
Publication of HUP0401097A2 publication Critical patent/HUP0401097A2/hu
Publication of HUP0401097A3 publication Critical patent/HUP0401097A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/24—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
    • C07C243/26—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C243/28—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of a saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/10—Hydrazines
    • C07C243/20—Hydrazines having nitrogen atoms of hydrazine groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Abstract

A találmány tárgyát képezi egy (I) általános képletű vegyület vagyannak egy izomerje vagy gyógyászatilag elfogadható szolvátja, hidrátjavagy sója, ahol a képletben Rl jelentése hidrogénatom vagy 1-4szénatomos alkil-, aralkil-, 2-5 szénatomos alkanoil-, aroil- vagyheteroaroil-csoport; R2 jelentése hidrogénatom, adott esetbenszubsztituált l-4 szénatomos alkil- vagy adott esetben szubsztituáltaralkilcsoport; R3-R5 és R10, amelyek lehetnek azonosak vagykülönbözőek, jelentése hidrogénatom, adott esetben szubsztituált 1-4szénatomos alkil-, adott esetben szubsztituált aralkil-; adott esetbenszubsztituált fenil- vagy adott esetben szubsztituált heteroaril-csoport; R3 és R10 cisz vagy transz térállásúak; R11 jelentésehidrogénatom, 1-4 szénatomos alkil-, 2-5 szénatomos alkanoil- vagyaralkilcsoport; R6--R9, amelyek lehetnek azonosak vagy különbözőek,jelentése hidrogénatom, adott esetben szubsztituált 1-4 szénatomosalkil-, halogénatom, hidroxil-, adott esetben szubsztituált 1-4szénatomos alkoxi-; adott esetben szubsztituált aralkoxi- vagy 1-4szénatomos alkilamino-csoport; n jelentése 1, 2 vagy 3, azzal amegkötéssel, hogy Rl metilcsoporttól különböző, ha R2 metilcsoport, ajelentése 1 és R3-R11 jelentése hidrogénatom.A találmány szerintivegyületek a gyógyászatban használhatóak -többek között gyulladásosbetegség, ezen belül például kötőszöveti, központi idegrendszeri,légzőszervi stb. gyulladásos betegség vagy állapot kezelésére szolgálógyógyszerekként. Különösen az akut és krónikus gyulladásos állapotokvagy betegségek, úgymint a krónikus arthritis, a gyulladásosbélbetegségek és a bőr dermatosisai, valamint a szénhidrát-anyagcserével, a zsírsejtek (adipociták) rendellenesdifferenciálódásával vagy működésével és a simaizomsejtek rendellenesműködésével kapcsolatos betegségek kezelhetőek a vegyületekkel.Atalálmány kiterjed a vegyületek előállítására és az ezeket tartalmazógyógyszerkészítményekre is. Ó
HU0401097A 2001-07-12 2002-07-11 Carbocyclic hydrazino inhibitors of copper-containing amine oxidases, process for their preparation and pharmaceutical compositions containing them HUP0401097A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/902,789 US6982286B2 (en) 2001-07-12 2001-07-12 Carbocyclic hydrazino inhibitors of copper-containing amine oxidases
PCT/FI2002/000630 WO2003006003A1 (en) 2001-07-12 2002-07-11 Carbocyclic hydrazino inhibitors of copper-containing amine oxidases

Publications (2)

Publication Number Publication Date
HUP0401097A2 true HUP0401097A2 (hu) 2004-09-28
HUP0401097A3 HUP0401097A3 (en) 2006-02-28

Family

ID=25416395

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0401097A HUP0401097A3 (en) 2001-07-12 2002-07-11 Carbocyclic hydrazino inhibitors of copper-containing amine oxidases, process for their preparation and pharmaceutical compositions containing them

Country Status (15)

Country Link
US (2) US6982286B2 (hu)
EP (1) EP1414426B1 (hu)
JP (1) JP4377221B2 (hu)
KR (1) KR20040017289A (hu)
CN (1) CN1520290A (hu)
AT (1) ATE318589T1 (hu)
CA (1) CA2451569A1 (hu)
DE (1) DE60209504T2 (hu)
ES (1) ES2259379T3 (hu)
HU (1) HUP0401097A3 (hu)
IL (1) IL159205A0 (hu)
NO (1) NO20035139D0 (hu)
RU (1) RU2004103869A (hu)
WO (1) WO2003006003A1 (hu)
ZA (1) ZA200309112B (hu)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982286B2 (en) * 2001-07-12 2006-01-03 Biotie Therapies Corp. Carbocyclic hydrazino inhibitors of copper-containing amine oxidases
FI20022007A0 (fi) * 2002-11-08 2002-11-08 Juvantia Pharma Ltd Oy Oromukosaalinen valmiste ja menetelmä sen valmistamiseksi
KR20120030601A (ko) * 2003-01-27 2012-03-28 아스텔라스세이야쿠 가부시키가이샤 티아졸 유도체 및 ｖａｐ-1 저해제로서의 용도
CA2520957C (en) * 2003-03-31 2013-08-06 Sucampo Ag Method for treating vascular hyperpermeable disease
AU2004241060B2 (en) * 2003-05-26 2009-07-23 Biotie Therapies Corp. Crystalline VAP-1 and uses thereof
FI20031927A0 (fi) * 2003-12-31 2003-12-31 Faron Pharmaceuticals Oy Terapeuttisesti vaikuttavia aineita ja niiden käyttö
US8119651B2 (en) * 2004-01-30 2012-02-21 Biotie Therapies Corp. Compositions useful especially for treatment or prevention of metabolic syndrome
CA2549029A1 (en) † 2004-01-30 2005-08-11 Faron Pharmaceuticals Oy Compositions for treatment or prevention of metabolic syndrome
FI20040136A0 (fi) * 2004-01-30 2004-01-30 Faron Pharmaceuticals Oy Erityisesti diabeetikoille soveltuvia koostumuksia
JP4140630B2 (ja) * 2005-11-10 2008-08-27 Ｔｄｋ株式会社 磁気ヘッドアセンブリ及び磁気ヘッドアセンブリの製造方法
US8372399B2 (en) 2006-08-31 2013-02-12 Cardiac Pacemakers, Inc. Bispecific antibodies and agents to enhance stem cell homing
US8636995B2 (en) * 2006-08-31 2014-01-28 Cardiac Pacemakers, Inc. Methods and devices to regulate stem cell homing
US20080058922A1 (en) * 2006-08-31 2008-03-06 Cardiac Pacemakers, Inc. Methods and devices employing vap-1 inhibitors
US20080207728A1 (en) * 2006-12-15 2008-08-28 Lars Wortmann Bicyclic acyltryptophanols
US20090170770A1 (en) * 2007-11-06 2009-07-02 Ali Hafezi-Moghadam Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap 1) inhibitor
US8906642B2 (en) 2008-09-03 2014-12-09 Universitat Autonoma De Barcelona Methods and compositions for the treatment and diagnosis of haemorrhagic conversion
WO2010033045A1 (en) * 2008-09-16 2010-03-25 Igor Anatolievich Pomytkin Compositions and methods for prevention or treatment of beta amyloid deposition
DK2376490T3 (da) 2008-12-04 2013-04-15 Proximagen Ltd Imidazopyridinforbindelser
UA112154C2 (uk) 2009-09-08 2016-08-10 Біоті Терапіс Корп. Застосування повністю людського анти-vap-1-антитіла для лікування фіброзних станів
GB201004311D0 (en) 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
FI20115234A0 (fi) 2011-03-08 2011-03-08 Biotie Therapies Corp Uusia pyridatsinoni- ja pyridoniyhdisteitä
WO2013037411A1 (en) 2011-09-14 2013-03-21 Proximagen Limited New enzyme inhibitor compounds
GB201115853D0 (en) 2011-09-14 2011-10-26 Proximagen Ltd New enzyme inhibitor compounds
GB201304527D0 (en) 2013-03-13 2013-04-24 Proximagen Ltd New compounds
GB201304526D0 (en) 2013-03-13 2013-04-24 Proximagen Ltd New compounds
CA2915163A1 (en) 2013-06-12 2014-12-18 Proximagen Limited New therapeutic uses of enzyme inhibitors
HUE042625T2 (hu) 2014-04-15 2019-07-29 Pecsi Tudomanyegyetem Szemikarbazid-szenzitiv amin-oxidáz gátlók fájdalomcsillapítóként való alkalmazásra traumás neuropátiában és neurogén gyulladásban
WO2015189534A1 (en) 2014-06-12 2015-12-17 Proximagen Limited Vap-1 inhibitors for treating muscular dystrophy
GB201416446D0 (en) 2014-09-17 2014-10-29 Proximagen Ltd New enzyme inhibitor compounds
GB201416444D0 (en) 2014-09-17 2014-10-29 Proximagen Ltd New compounds
GB201521541D0 (en) * 2015-12-07 2016-01-20 Proximagen Ltd New therapeutic uses of enzyme inhibitors
EP3386494A1 (en) 2015-12-07 2018-10-17 Benevolentai Cambridge Limited Vap-1 inhibitors for treating pain
GB201709136D0 (en) * 2017-06-08 2017-07-26 Proximagen Ltd New therapeutic uses of enzyme inhibitors
CN107935993A (zh) * 2017-12-29 2018-04-20 佛山汉方中医医院有限公司 甲基金刚烷和硝基吡啶结构衍生物、其制备方法及其用途
CN108084155A (zh) * 2017-12-29 2018-05-29 佛山汉方中医医院有限公司 甲基金刚烷和烷氧吡啶结构的ssao抑制剂及其用途
CN108033946A (zh) * 2017-12-29 2018-05-15 佛山汉方中医医院有限公司 一种含金刚烷结构的ssao抑制剂、制备方法及其用途
CN107915719A (zh) * 2017-12-29 2018-04-17 佛山汉方中医医院有限公司 一类甲基金刚烷和吡啶结构的ssao抑制剂及其用途
CN107935989A (zh) * 2017-12-29 2018-04-20 佛山汉方中医医院有限公司 金刚烷和腈基吡啶结构化合物、其制备方法及用途
CN108129458A (zh) * 2017-12-29 2018-06-08 佛山汉方中医医院有限公司 一种金刚烷和二甲胺吡啶结构衍生物、其制备方法及用途
CN108191823A (zh) * 2017-12-29 2018-06-22 佛山汉方中医医院有限公司 一类烷基取代金刚烷ssao抑制剂、制备方法及其用途
CN109988147A (zh) * 2017-12-29 2019-07-09 佛山汉方中医医院有限公司 含金刚烷结构的ssao抑制剂、制备方法及其用途
CN108033945A (zh) * 2017-12-29 2018-05-15 佛山汉方中医医院有限公司 一种金刚烷和硝基吡啶结构化合物及用途
CN107935990A (zh) * 2017-12-29 2018-04-20 佛山汉方中医医院有限公司 含金刚烷和烷氧吡啶结构化合物、其制备方法及用途
CN108084154A (zh) * 2017-12-29 2018-05-29 佛山汉方中医医院有限公司 一种金刚烷和胺基吡啶结构衍生物、其制备方法及用途
CN108191824A (zh) * 2017-12-29 2018-06-22 佛山汉方中医医院有限公司 一种甲基金刚烷和二甲胺吡啶结构衍生物、其制备方法及其用途
CN108191825A (zh) * 2017-12-29 2018-06-22 佛山汉方中医医院有限公司 一种甲基金刚烷和硝基吡啶结构衍生物及其用途
CN107935992A (zh) * 2017-12-29 2018-04-20 佛山汉方中医医院有限公司 一类含金刚烷和卤代吡啶结构化合物及用途
SE544131C2 (en) * 2020-03-16 2022-01-04 Pvac Medical Tech Ltd Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3105849A (en) * 1960-02-01 1963-10-01 Ciba Geigy Corp Bicyclic hydrazinium compounds
AU8031598A (en) 1997-06-05 1998-12-21 Venantius Limited 3-aminoindane derivatives, process for their preparation and pharmaceutical compositions containing them
WO1998055439A1 (en) 1997-06-05 1998-12-10 Venantius Limited Indane compounds and their pharmaceutical use
HUP0301625A3 (en) 2000-07-05 2005-04-28 Biotie Therapies Corp 1,3,4-oxadiazine-compounds as inhibitors of copper-containing amine oxidases, process for their preparation and their use for preparation of pharmaceutical compositions
US6982286B2 (en) * 2001-07-12 2006-01-03 Biotie Therapies Corp. Carbocyclic hydrazino inhibitors of copper-containing amine oxidases

Also Published As

Publication number Publication date
US20040236108A1 (en) 2004-11-25
DE60209504D1 (de) 2006-04-27
HUP0401097A3 (en) 2006-02-28
US20030125360A1 (en) 2003-07-03
IL159205A0 (en) 2004-06-01
ATE318589T1 (de) 2006-03-15
EP1414426B1 (en) 2006-03-01
EP1414426A1 (en) 2004-05-06
KR20040017289A (ko) 2004-02-26
ES2259379T3 (es) 2006-10-01
CA2451569A1 (en) 2003-01-23
JP4377221B2 (ja) 2009-12-02
NO20035139D0 (no) 2003-11-19
US6982286B2 (en) 2006-01-03
WO2003006003A1 (en) 2003-01-23
DE60209504T2 (de) 2006-10-12
JP2005501035A (ja) 2005-01-13
ZA200309112B (en) 2004-07-23
CN1520290A (zh) 2004-08-11
RU2004103869A (ru) 2005-03-27

Similar Documents

Publication Publication Date Title
HUP0401097A2 (hu) Karbociklusos hidrazinovegyületek, mint a réztartalmú aminoxidázok inhibitorai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP9900172A2 (hu) Idegrendszeri elváltozások kezelésére alkalmas 10-aciloxi-10,11-dihidrobenz/b,f/azepin-5-karboxamid, előállítása és ezt tartalmazó gyógyszerkészítmény
TWI255807B (en) Therapeutic agents
HUP9600448A2 (hu) Naftilvegyületek, e vegyületeket tartalmazó gyógyszerkészítmények, eljárás előállításukra, intermedierjeik és alkalmazásuk
MXPA05013712A (es) Derivados de acido propionico, utiles en el tratamiento de trastornos de lipidos.
WO2014164867A1 (en) Kdm1a inhibitors for the treatment of disease
HUP0002960A2 (hu) Aril-oxi-szulfonil-amino-hidroxámsav-származékok
HUP0003644A2 (hu) 2,3-Diaril-pirazolo[1,5-b]piridazin-származékok, ezeket tartalmazó gyógyászati készítmények ciklooxigenáz 2(COX-2) gátlására, valamint eljárás a vegyületek előállítására
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
HUP0101130A2 (hu) Aminoindánszármazékok és ezeket tartalmazó gyógyászati készítmények
AU2002359164A1 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer&#39;s disease and conditions associated with glycogen synthase kinase-3
GB0225475D0 (en) Therapeutic agents
EP1689713A4 (en) BENZYLETHER AND BETA-SECRETASE BENZYLAMINO INHIBITORS FOR TREATING ALZHEIMER&#39;S DISEASE
IL163629A0 (en) Glutaminyl derivatives and pharmaceutical compositions containing the same
EP1673078A4 (en) BENZYL ETHER AND BENZYLAMINO BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE
MY149182A (en) Phenyl-[1,2,4]-oxadiazol-5-one derivatives with phenyl group, processes for their preparation and their use as pharmaceuticals
HUP0401192A2 (hu) Fényérzékenyítő szer alkalmazása sebek kezelésére adható gyógyászati készítmény előállítására
TW200505862A (en) 2-amino-pyridine derivatives useful for the treatment of diseases
IL178167A0 (en) 1,3,4-oxadiazol-2-ones as ppar delta modulators
PT1747220E (pt) 1h-pirrolo[3,2-b, 3,2-c e 2,3-c]piridina-2-carboxamidas e análogos relacionados como inibidores da caseína-cinase i epsilon
MX2020003383A (es) Compuesto de griseofulvina y uso farmacéutico de este.
TW200505865A (en) Compounds useful for the treatment of diseases
ATE367387T1 (de) Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden
NL300198I2 (nl) Toepassing van 2-(2-nitro-4-trifluormethylbenzoyl)cyclohexaandion-1,3 voor het behandelen van tyrosinemie, alsmede farmaceutische preparaten.

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees